Molecular structure of (S)-HDAC-42, CAS Number: 935881-37-1
(S)-HDAC-42 (CAS 935881-37-1)
Alternate Names:
AR-42
Application:
(S)-HDAC-42 is a potent inhibitor of HDAC
CAS Number:
935881-37-1
Purity:
≥95%
Molecular Weight:
312.4
Molecular Formula:
C18H20N2O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
(S)-HDAC-42 is a potent inhibitor of HDAC (IC50 = 16 nM in vitro). (S)-HDAC-42 decreases the viability of prostate cancer cell lines (IC50 = 0.40 muM), increasing the expression of p21 and the acetylation of histone H3 while decreasing the phosphorylation of Akt and the expression of Bcl-XL. (S)-HDAC-42 also strongly suppresses the growth of PC-3 tumor xenografts, reducing levels of phospho-Akt and Bcl-XL protein in tumors.
(S)-HDAC-42 (CAS 935881-37-1) References
- Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. | Dai, Y., et al. 2008. Clin Cancer Res. 14: 7701-10. PMID: 19047096
- AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. | Lin, TY., et al. 2010. Blood. 115: 4217-25. PMID: 20233974
- Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. | Cheng, H., et al. 2016. AAPS J. 18: 737-45. PMID: 26943915
- AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition. | Zhang, M., et al. 2016. Oncotarget. 7: 22285-94. PMID: 26993777
- Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. | Murahari, S., et al. 2017. BMC Cancer. 17: 67. PMID: 28109246
- The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis. | Elshafae, SM., et al. 2017. Prostate. 77: 776-793. PMID: 28181686
- Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU. | Zhou, R., et al. 2018. Oncol Lett. 16: 1967-1974. PMID: 30008890
- Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition. | Wei, D., et al. 2018. Life Sci. 211: 224-237. PMID: 30248347
- Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer. | Kulp, SK., et al. 2019. Clin Cancer Res. 25: 2940. PMID: 31043388
- Histone deacetylase inhibitor, AR-42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells. | Duan, S., et al. 2019. J Cell Physiol. 234: 22411-22423. PMID: 31102271
- Anti-oral Squamous Cell Carcinoma Effects of a Potent TAZ Inhibitor AR-42. | Su, L., et al. 2020. J Cancer. 11: 364-373. PMID: 31897232
- Phase I study of AR-42 and decitabine in acute myeloid leukemia. | Liva, SG., et al. 2020. Leuk Lymphoma. 61: 1484-1492. PMID: 32037935
- Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice. | Chua, MJ., et al. 2021. Int J Parasitol Drugs Drug Resist. 17: 118-127. PMID: 34560571
- The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors. | Elshafae, SM., et al. 2021. Cancers (Basel). 13: PMID: 34680215
Inhibitor of:
ASXL3, BAGE4, BRMS1L, GAGE12G, H3.Y histone 1, Hat2, HDAC, LIN-35, MAGE-A9B, MAGE-B1, MAGE-B3, and MRG15.Activator of:
BAF53B, C14orf135, Histone cluster 1 H2AA2, MPc3_CBX8, PABPC4, Smurf2, and ZNF579.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(S)-HDAC-42, 1 mg | sc-296364 | 1 mg | $96.00 | |||
(S)-HDAC-42, 5 mg | sc-296364A | 5 mg | $417.00 |